Douglas Robinson

951 total citations
15 papers, 481 citations indexed

About

Douglas Robinson is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Douglas Robinson has authored 15 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Genetics. Recurrent topics in Douglas Robinson's work include HER2/EGFR in Cancer Research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Douglas Robinson is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Douglas Robinson collaborates with scholars based in United States, France and Italy. Douglas Robinson's co-authors include Humphrey Gardner, Jason Chesney, Kevin B. Kim, Michael Shi, John M. Kirkwood, Guy Jérusalem, Masakazu Toi, Fabrice André, Howard A. Burris and David Chen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Douglas Robinson

13 papers receiving 472 citations

Peers

Douglas Robinson
Prateek Mendiratta United States
James A. Onori United States
Friedrich Graf Finckenstein United States
Hidenori Mizugaki Japan
Brianne Kaiser United States
Greg Friberg United States
P. Dieringer United States
Barbara Szostakiewicz Poland
Karl Hsu United States
Takashi Nakaoku Japan
Prateek Mendiratta United States
Douglas Robinson
Citations per year, relative to Douglas Robinson Douglas Robinson (= 1×) peers Prateek Mendiratta

Countries citing papers authored by Douglas Robinson

Since Specialization
Citations

This map shows the geographic impact of Douglas Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Robinson more than expected).

Fields of papers citing papers by Douglas Robinson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Robinson. The network helps show where Douglas Robinson may publish in the future.

Co-authorship network of co-authors of Douglas Robinson

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Robinson. A scholar is included among the top collaborators of Douglas Robinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Robinson. Douglas Robinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Collins, Jamie E., Peter Mesenbrink, Erik B. Dam, et al.. (2025). Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression. ACR Open Rheumatology. 7(9). e70085–e70085. 1 indexed citations
2.
Collins, Jamie E., Douglas Robinson, Nigel Arden, et al.. (2025). Biochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study. Osteoarthritis and Cartilage Open. 7(4). 100677–100677.
3.
Otter, Verena & Douglas Robinson. (2024). Transparency and changing stakeholder roles in the digital age of sustainable agri-food supply chain networks. Frontiers in Sustainable Food Systems. 8. 4 indexed citations
4.
Robinson, Douglas, Sebastian Lakner, & Verena Otter. (2024). Are German pastures greener for Chinese dairy foreign direct investments?. The International Food and Agribusiness Management Review. 27(4). 745–764. 3 indexed citations
5.
Pistilli, Barbara, Timothy Pluard, Ander Urruticoechea, et al.. (2017). Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. 168(2). 357–364. 50 indexed citations
6.
André, Fabrice, Sara A. Hurvitz, Angelica Fasolo, et al.. (2016). Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology. 34(18). 2115–2124. 135 indexed citations
7.
8.
Slamon, Dennis J., Sara A. Hurvitz, David Chen, et al.. (2015). Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. Journal of Clinical Oncology. 33(15_suppl). 512–512. 14 indexed citations
9.
Jérusalem, Guy, Fabrice André, David Chen, et al.. (2013). Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial. Open Repository and Bibliography (University of Liège). 49. 12 indexed citations
10.
11.
Amakye, Dereck D., Douglas Robinson, Kristine Rose, et al.. (2012). Abstract 4818: The predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for Hedgehog pathway inhibitor therapy. Cancer Research. 72(8_Supplement). 4818–4818. 9 indexed citations
12.
Kim, Kevin B., Jason Chesney, Douglas Robinson, et al.. (2011). Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma. Clinical Cancer Research. 17(23). 7451–7461. 100 indexed citations
13.
Huang, Fei, Ann Greer, Warren Hurlburt, et al.. (2008). The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors. Cancer Research. 69(1). 161–170. 137 indexed citations
14.
Robinson, Douglas, David Mauro, Christine Chung, et al.. (2008). Utility of cetuximab-cross reactive IgE as a predictive biomarker for cetuximab associated severe infusion reactions. Clinical Cancer Research. 14. 1 indexed citations
15.
Carnés, Jerónimo & Douglas Robinson. (2008). New Strategies for Allergen Immunotherapy. Recent Patents on Inflammation & Allergy Drug Discovery. 2(2). 92–101. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prateek Mendiratta Breakdown of academic impact, for papers by James A. Onori Breakdown of academic impact, for papers by Friedrich Graf Finckenstein Breakdown of academic impact, for papers by Hidenori Mizugaki Breakdown of academic impact, for papers by Brianne Kaiser Breakdown of academic impact, for papers by Greg Friberg Breakdown of academic impact, for papers by P. Dieringer Breakdown of academic impact, for papers by Barbara Szostakiewicz Breakdown of academic impact, for papers by Karl Hsu Breakdown of academic impact, for papers by Takashi Nakaoku
Rankless by CCL
2026